Accomplishments for 2010

The Sickle Cell Cure Foundation, Inc. (SCCF) is a non-profit 501(c)(3) research foundation incorporated in 2006. SCCF chose the PHF Research Park as its world headquarters to conduct translational research using patented treatments aimed at curing two of mankind’s most devastating diseases: malaria and its allied blood disorder, sickle cell disease (SCD). The Bill & Melinda Gates Foundation recently awarded a Grand Challenge Exploration grant to SCCF to conduct its animal safety and efficacy trials. SCCF aims to raise additional funds for human clinical trials required for FDA approval. The therapeutics offered by SCCF are inexpensive, non-invasive, and easy to deliver; and SCCF’s mission fits the Gates’ central philanthropic principle that “all lives have equal value”.

The mission of the SCCF is to bring the affordable, patented cure we have discovered to the millions of malaria and SCD sufferers around the world. The treatment SCCF offers is termed Gene Regulation Therapy (GRT).

Recent accomplishments of the SCCF include:

  • Patents issued in the U.S., Europe, and Australia
    US Patent # 7,517,669 Issued April 14, 2009
    US Patent # 7,718,699 Issued May 18, 2010
    US Patent Pending # 0232783 A1 Sept. 17, 2009
    EU Patent # EP Patent 1,354,032 B1 Sept. 08, 2006
    AU Patent # 2002217964 March 03, 2006
  • Grand Challenges Explorations Grant awarded by the Bill & Melinda Gates Foundation, May 1, 2010
  • New SCCF office at 601 NW 13th St., Oklahoma City, OK, May 1, 2009.
  • SCCF Laboratory opened in the PHF Research Park, Oklahoma City, OK, May 1, 2010.
  • SCCF currently maintains active IRB and IACUC protocols at OUHSC.
  • Animal safety & efficacy trials for SCCF’s patented treatments for sickle cell disease and malaria started Nov. 1, 2010.
  • SCCF seeks international partners for clinical trials and worldwide distribution of its patented treatments. See contact information below.

SCCF’s business plan for global distribution of Gene Regulation Therapy for SCD estimates a 95% drop in the cost of standard Western treatments. Whereas current treatments only address the symptoms of SCD, SCCF’s approach corrects the primary cause. For the world’s poor majority, SCCF’s business model uses cross-subsidy pricing to deliver the cure to Africa pharmaceutical outlets for as little as US $12.00 per person per year.

Speak Your Mind

*